Reta Dosage: Research Protocols for Triple Agonist Studies
Retatrutide Research
Triple GIP/GLP-1/GcgR Agonism
Last Updated: May 2026
Prescription-Only Medicine — Important Notice
Retatrutide is a novel investigational compound. In jurisdictions where GLP-1 receptor agonists are regulated as prescription medicines, similar regulatory considerations may apply. Pure Grade Labs supplies retatrutide strictly for laboratory research purposes only — not for human consumption, self-administration, or therapeutic use. This article explains what the clinical trials studied, not how to self-administer.
Searches for “Reta dosage” reflect a specific, informed type of researcher: someone tracking the clinical trial data for retatrutide — the triple agonist that has produced the highest body weight reduction data ever published in a pharmacological obesity trial — and trying to understand what dose levels were actually studied and why. This article answers that question directly. Reta (retatrutide) is not an approved medicine — no prescribing information, no authorised product insert, no licensed indication exists as of 2026. It is an investigational compound currently in Phase III trials at Eli Lilly. The Reta dosage data that exists comes entirely from published Phase I and Phase II clinical research, and that is precisely what this article covers: the dose-finding and escalation designs that researchers need to understand to contextualise retatrutide’s pharmacology, and why the lack of approved prescribing information makes Reta dosage even more of a research-critical topic than for approved GLP-1 compounds. Pure Grade Labs supplies research-grade Retatrutide 10mg for laboratory investigation only — not for human consumption. This article is about the trial literature, not about clinical guidance.
Key Takeaways
- Reta is a triple agonist — the first in its class: Retatrutide simultaneously activates three metabolic receptors — the GIP receptor, the GLP-1 receptor, and the glucagon receptor (GcgR). This triple mechanism distinguishes it from tirzepatide (dual GIP/GLP-1) and semaglutide (GLP-1 only) and is the central research interest driving Reta peptide dosage investigation.
- Phase II NEJM data: 24.2% mean body weight reduction at 12mg: The Phase II retatrutide trial (Jastreboff et al. 2023, NEJM) reported a mean body weight reduction of 24.2% at the 12mg weekly dose over 48 weeks — the highest weight reduction figure published in any GLP-1 class clinical trial to date. This is the landmark Reta dosage finding that has driven research interest globally.
- Retatrutide dosage studied in Phase II: 1mg, 4mg, 8mg, 12mg weekly: Four dose levels were investigated in the Phase II 48-week escalating-dose trial. Escalation was designed to manage GI tolerability — doses were titrated up over the first weeks of the protocol rather than administered at target dose from the outset.
- Retatrutide is not approved anywhere — no prescribing information exists: Unlike semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro), retatrutide has no approved indication, no MHRA or FDA licence, and no commercially available product. Any Reta dosage discussion outside the trial literature is extrapolation — which makes the Phase I and II data the only legitimate reference point for researchers.
- Pure Grade Labs supplies Retatrutide for laboratory research: Retatrutide 10mg is available at ≥99% HPLC-verified purity with batch-specific COA for in vitro and preclinical research. Prescription-only medicine in many jurisdictions. Not for human consumption.
Research-Grade Retatrutide — UK Supply
Retatrutide 10mg for laboratory research. 99%+ HPLC-verified purity. Batch COA included. Not for human consumption.
Investigational compound. Prescription-only medicine in many jurisdictions. For research purposes only.
What Is Reta? Understanding Retatrutide as a Triple Agonist
Reta — the research shorthand for retatrutide — is a synthetic peptide developed by Eli Lilly that simultaneously agonises three distinct G protein-coupled receptors involved in metabolic regulation: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor (GcgR). This triple mechanism of action sets Reta apart from every other compound in the incretin agonist class and is the pharmacological basis for its extraordinary Phase II efficacy data.
To understand why the triple agonism matters, it helps to understand the progression of the class. Semaglutide (Ozempic, Wegovy) is a monoagonist — it targets the GLP-1 receptor only. GLP-1 receptor agonism reduces appetite through central nervous system pathways, slows gastric emptying, and improves glycaemic control through glucose-dependent insulin secretion. Semaglutide 2.4mg (the obesity dose, Wegovy) produced a mean body weight reduction of approximately 14.9% in the STEP-1 trial over 68 weeks — a landmark result that established the GLP-1 class as the most efficacious pharmacological treatment for obesity studied to that point.
Tirzepatide (Mounjaro) extended this by adding GIP receptor agonism — creating a dual agonist. GIP receptor signalling contributes to insulin secretion, modulates fat metabolism, and appears to amplify the weight reduction effects of GLP-1 receptor stimulation through mechanisms that are still being characterised in research. The SURMOUNT-1 trial at tirzepatide 15mg produced a mean body weight reduction of 20.9% over 72 weeks — exceeding semaglutide’s STEP-1 outcomes and establishing tirzepatide as the efficacy leader in the class at the time of its publication.
Retatrutide adds the third dimension: glucagon receptor (GcgR) agonism. Glucagon is primarily known as a counter-regulatory hormone that raises blood glucose, but glucagon receptor agonism in the context of co-administration with GLP-1 receptor agonists has a different effect profile. GcgR agonism is hypothesised to increase energy expenditure directly — an effect mediated through thermogenic brown adipose tissue activation and hepatic fatty acid oxidation. Additionally, glucagon receptor agonism may enhance lipolysis in adipose tissue, potentially mobilising hepatic fat stores in ways that pure incretin agonism does not achieve. This additional energy expenditure component — layered on top of the appetite suppression from GLP-1 agonism and the amplification effects from GIP agonism — is the research hypothesis underpinning why Reta’s trial data exceeds tirzepatide’s.
Retatrutide has CAS number 2381627-57-0 and an approximate molecular weight of 4,869 Da. It has a half-life of approximately 6 days — supporting the once-weekly subcutaneous dosing schedule used in both Phase I and Phase II trial designs.
What Phase I Studied: First-in-Human Reta Dosage Data
The Phase I first-in-human study for retatrutide was designed to assess safety, tolerability, and pharmacokinetics across a range of single ascending doses and then multiple ascending doses in healthy participants. Phase I trials are not designed to test efficacy — they are designed to establish that a compound is safe to administer to humans, to characterise how it is absorbed and eliminated, and to identify the dose range that is tolerable before more extensive Phase II efficacy studies begin.
In the retatrutide Phase I programme, single subcutaneous doses were investigated from 0.5mg through to 12mg. Multiple-dose escalation cohorts then evaluated weekly dosing at escalating doses across an extended period. The safety profile that emerged from Phase I was consistent with the GI adverse event profile typical of the incretin agonist class — nausea, vomiting, and decreased appetite, predominantly occurring during dose escalation and diminishing with continued administration. No new safety signals outside the expected class profile were identified in Phase I, which provided the regulatory and clinical basis for advancing to Phase II.
The pharmacokinetic data from Phase I confirmed the approximately 6-day half-life, the linearity of exposure across dose levels, and the accumulation characteristics that supported once-weekly dosing as the appropriate Phase II administration frequency. These PK parameters are directly relevant to researchers studying retatrutide’s receptor binding kinetics and the duration of receptor engagement relative to circulating compound concentration.
What Phase II Studied: The NEJM-Published Reta Dosage Outcomes
The Phase II retatrutide trial — published by Jastreboff AM and colleagues in the New England Journal of Medicine in 2023 — is the primary reference for Reta dosage research. It is the study that generated the 24.2% weight reduction figure that has driven research interest in this compound globally.
The trial enrolled 338 adults with obesity (BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity) who did not have type 2 diabetes. Participants were randomised to placebo or one of four retatrutide dose groups — 1mg, 4mg, 8mg, or 12mg — administered as weekly subcutaneous injections over 48 weeks. All dose groups used an escalating schedule: rather than beginning at the target dose, participants started at a lower initiation dose and escalated progressively to allow GI tolerability to develop. This escalation design is standard for the incretin agonist class.
Phase II Retatrutide Dosage Findings by Dose Group
The trial demonstrated a clear dose-response relationship across all four retatrutide dosage groups:
- 1mg weekly: Mean body weight reduction of approximately 8.7% over 48 weeks — modest but statistically significant versus placebo.
- 4mg weekly: Mean body weight reduction of approximately 17.3% over 48 weeks — approaching tirzepatide’s SURMOUNT-1 outcomes at a lower dose.
- 8mg weekly: Mean body weight reduction of approximately 22.8% over 48 weeks — exceeding tirzepatide 15mg from SURMOUNT-1 at a lower nominal dose.
- 12mg weekly: Mean body weight reduction of approximately 24.2% over 48 weeks — the highest weight reduction figure published for any pharmacological intervention in a clinical trial at time of publication. Notably, weight loss trajectory appeared to not yet plateau at 48 weeks, suggesting higher sustained outcomes may be achievable with longer study duration.
Adverse events in the Phase II trial were primarily gastrointestinal — nausea, diarrhoea, vomiting, and decreased appetite — consistent with the class profile of all GLP-1 receptor agonists and incretin-based compounds. These events were dose-dependent in frequency and severity and were most common during dose escalation phases. The incidence of serious adverse events was similar across dose groups and did not identify any novel safety concern not previously associated with GLP-1 receptor agonist pharmacology. No new off-target safety signals were attributed to the additional glucagon receptor agonism in the Phase II population.
Reta vs Tirzepatide vs Semaglutide: The Research Hierarchy
For researchers contextualising where retatrutide dosage data sits relative to the existing approved incretin agonist class, the published trial literature creates a clear hierarchy of efficacy outcomes across the three generations of this compound class:
| Compound | Mechanism | Peak Dose Studied | Mean Body Weight Reduction | Trial / Duration |
|---|---|---|---|---|
| Semaglutide | GLP-1 monoagonist | 2.4mg weekly | −14.9% | STEP-1 (68 weeks) |
| Tirzepatide | GIP + GLP-1 dual agonist | 15mg weekly | −20.9% | SURMOUNT-1 (72 weeks) |
| Retatrutide (Reta) | GIP + GLP-1 + Glucagon triple agonist | 12mg weekly | −24.2% | Phase II NEJM 2023 (48 weeks) — weight loss not plateaued |
This table represents the most direct published comparison available across the three compounds. It is important to note that these are not head-to-head trial results — each figure comes from a separate trial with different enrolled populations, different trial durations, and different study designs. Direct cross-trial comparisons carry the limitations inherent in comparing different study populations. However, the absolute magnitude of the efficacy differences — particularly the 24.2% at 48 weeks for Reta versus 20.9% at 72 weeks for tirzepatide — is sufficiently large that the research community broadly accepts the comparative hierarchy as reflecting genuine pharmacological differences rather than statistical noise.
For researchers, the particularly interesting observation is that the retatrutide Phase II weight loss curve had not plateaued at 48 weeks — the trajectory at study end still appeared to be declining. Head-to-head trials would be needed to rigorously quantify any difference, but the research interest this data generates is what has driven search volume for Reta dosage and retatrutide research protocols to levels that rival compounds with approved indications.
The Glucagon Receptor Component: What It Adds to Reta Dosage Research
The distinguishing research question around retatrutide dosage — relative to tirzepatide or semaglutide — centres on the pharmacological contribution of the glucagon receptor (GcgR) agonism component. Glucagon is a 29-amino acid peptide produced by alpha cells of the pancreatic islets, classically characterised as the counter-regulatory hormone to insulin. Its canonical function is to raise blood glucose during fasting by stimulating hepatic glycogenolysis and gluconeogenesis. This raises an apparent paradox: if glucagon raises blood glucose, how can a glucagon receptor agonist contribute to the metabolic benefits observed with retatrutide?
The resolution lies in context-dependent GcgR signalling. When glucagon receptor agonism is co-administered with potent GLP-1 receptor agonism, the insulin-stimulating and glucose-lowering effect of GLP-1 receptor signalling is hypothesised to counteract the glycaemic consequences of glucagon receptor activation — while preserving the non-glycaemic effects of GcgR signalling. These non-glycaemic GcgR-mediated effects are the subject of active research and include:
- Direct energy expenditure increase: GcgR agonism has been shown in rodent models to activate thermogenic brown adipose tissue, increasing resting metabolic rate. This energy expenditure effect is distinct from the appetite suppression mechanism of GLP-1 agonism and may provide an additive mechanism for weight reduction that pure incretin agonism cannot access.
- Hepatic fat mobilisation: Glucagon receptor signalling in the liver drives fatty acid oxidation and has been studied in the context of non-alcoholic fatty liver disease (NAFLD) models. The research hypothesis is that GcgR agonism in retatrutide may contribute to hepatic fat reduction beyond what is achievable with incretin agonism alone.
- Lipolysis enhancement: GcgR agonism in adipose tissue is hypothesised to facilitate the mobilisation of stored fat, potentially contributing to the preferential fat mass reduction (versus lean mass) suggested in early retatrutide body composition data.
These mechanistic hypotheses remain under active investigation in the Phase III programme. The published Phase II data demonstrates the efficacy signal but cannot fully attribute the incremental benefit over tirzepatide specifically to GcgR agonism — this mechanistic attribution will require dedicated receptor antagonism studies and more detailed body composition and indirect calorimetry sub-studies in Phase III. This is precisely the type of mechanistic investigation that makes retatrutide a compelling research tool for laboratory researchers studying GcgR pharmacology and the metabolic consequences of triple receptor co-agonism.
Triple Agonist Research Supply — Retatrutide UK
Retatrutide 10mg. HPLC ≥99% purity. Batch-specific COA. UK stock. For laboratory research only.
Investigational compound. Not for human consumption. Prescription-only considerations apply in many jurisdictions.
Why Reta Dosage Requires Extra Caution: Pre-Approval Status
The absence of approved prescribing information for retatrutide is not a technicality — it is a fundamental distinction that places Reta dosage research in a different category from approved compounds like semaglutide or tirzepatide.
When a medicine is approved by a regulatory body like the MHRA or FDA, that approval process includes a comprehensive benefit-risk assessment across the full trial programme, safety data from tens of thousands of patients, and the development of detailed prescribing information specifying contraindications, drug interactions, populations at elevated risk, and management of adverse events. This information — contained in the Summary of Product Characteristics (SmPC) for approved medicines — represents the distilled clinical judgement of regulators with access to all trial data including unpublished results and post-marketing safety signals.
None of this exists for retatrutide. The Phase II data provides efficacy and general tolerability information for a specific studied population in a controlled trial setting. Phase III data, if and when published, will provide more. But as of 2026, retatrutide has no approved indication, no SmPC, no contraindication database, no established drug interaction profile from large-population real-world data, and no long-term safety data beyond the Phase II 48-week observation window. The glucagon receptor agonism component introduces receptor targets — particularly hepatic and cardiovascular GcgR signalling — whose full pharmacological consequences in diverse human populations have not been characterised across the extended time horizons that post-marketing safety surveillance would provide.
This context is why retatrutide dosage data — even within the published trial literature — represents research findings from specific, selected trial populations under controlled conditions, not generalised prescribing guidance. Pure Grade Labs supplies retatrutide strictly for laboratory research. This article is about what the trials studied. It is not a self-administration guide.
Research Applications for Retatrutide: What Laboratories Study
For researchers studying incretin pharmacology, triple receptor co-agonism, and metabolic signalling pathways, retatrutide is a research tool of significant interest precisely because it is a pre-approval compound with published Phase II data — meaning there is a defined pharmacological profile to investigate mechanistically, a rich efficacy dataset to contextualise findings against, and open questions about mechanism of action that laboratory research can contribute to answering.
Triple Receptor Co-Agonism Studies
In vitro and cell-based research using retatrutide can characterise its binding affinity and functional agonist activity at GIP receptors, GLP-1 receptors, and GcgR in appropriate cell models. The relative potency of retatrutide at each of the three receptor targets — and how co-agonism at multiple receptors simultaneously affects downstream cAMP signalling, receptor internalisation, and desensitisation kinetics — are active areas of investigation. Comparative research combinations using retatrutide alongside tirzepatide and semaglutide allow researchers to isolate the incremental contribution of GcgR agonism to cell-level signalling outcomes.
Glucagon Receptor Pharmacology and Energy Expenditure Models
The glucagon receptor agonism component of retatrutide is the least well-characterised element of its pharmacology relative to its GIP and GLP-1 components. Research into brown adipose tissue thermogenesis models, hepatic fatty acid oxidation assays, and adipose lipolysis assays using retatrutide at defined concentrations can help characterise the receptor-level mechanisms by which GcgR co-agonism contributes to energy expenditure. This research is directly relevant to the Phase III hypothesis being tested in ongoing Eli Lilly trials.
Comparative Metabolic Research Combinations
The Metabolic Research Stack from Pure Grade Labs supports researchers investigating metabolic signalling across multiple receptor systems within a single research programme. For investigators comparing the metabolic receptor pharmacology of the incretin agonist generation — from GLP-1 monoagonism through dual agonism to triple agonism — having all three reference compounds at research grade allows meaningful within-lab comparison that minimises inter-batch variability as a confounding variable.
“The 24.2% figure from the Jastreboff 2023 NEJM paper landed in the research community like a dropped gauntlet. At 48 weeks — not 68 or 72 — and with weight loss trajectory still declining. Metabolic pharmacologists tracking the GLP-1 class understood immediately what the glucagon receptor component meant as a mechanistic hypothesis: not just appetite suppression, but direct energy expenditure. Not just incretin amplification, but fat mobilisation at the hepatic level. The Reta dosage data was not just an efficacy outcome. It was a hypothesis about what three-receptor co-agonism could do that two-receptor or one-receptor approaches could not. That hypothesis is what researchers are now working to characterise at the cellular level — which is exactly where laboratory research tools matter.”
Frequently Asked Questions: Reta Dosage and Retatrutide Research
What doses were studied in the retatrutide Phase II trial?
The Phase II retatrutide trial (Jastreboff et al. 2023, NEJM) studied four Reta dosage groups in 338 adults with obesity over 48 weeks: 1mg, 4mg, 8mg, and 12mg administered as weekly subcutaneous injections with an escalating dose-titration schedule. Mean body weight reductions were approximately 8.7%, 17.3%, 22.8%, and 24.2% respectively. The 12mg dose group showed the highest efficacy, with weight loss trajectory not plateaued at the 48-week endpoint.
How does Reta dosage compare to tirzepatide and semaglutide in published trials?
Across published Phase II/III trial data, the mean body weight reduction at the highest studied doses shows a clear hierarchy: retatrutide 12mg achieved 24.2% at 48 weeks (Phase II, NEJM 2023); tirzepatide 15mg achieved 20.9% at 72 weeks (SURMOUNT-1, NEJM 2022); semaglutide 2.4mg achieved 14.9% at 68 weeks (STEP-1, NEJM 2021). These comparisons come from separate trials with different populations and durations — they are not head-to-head data. However, the absolute magnitude of differences is considered by researchers to be pharmacologically meaningful.
Is retatrutide approved for use in the UK?
No. As of 2026, retatrutide has no approved indication anywhere in the world. It is an investigational compound in Phase III clinical trials at Eli Lilly. No prescribing information, Summary of Product Characteristics, or regulatory approval exists. This means there is no authorised therapeutic dose, no prescriber pathway, and no licensed product. Pure Grade Labs supplies retatrutide strictly as a research chemical for laboratory investigation only — not for human consumption or self-administration.
What makes retatrutide different from tirzepatide as a research tool?
Retatrutide adds glucagon receptor (GcgR) agonism to the GIP/GLP-1 dual mechanism of tirzepatide. GcgR agonism is hypothesised to increase energy expenditure through brown adipose tissue thermogenesis, enhance hepatic fatty acid oxidation, and facilitate adipose lipolysis — mechanisms not directly engaged by incretin agonism alone. For researchers studying the comparative pharmacology of the incretin agonist class, the additional GcgR component creates a research opportunity to isolate and characterise the metabolic effects attributable to glucagon receptor co-stimulation in the context of GIP/GLP-1 receptor background activation.
What is the half-life of retatrutide and why does it matter for research design?
Retatrutide has a half-life of approximately 6 days, which supports once-weekly dosing in clinical trial designs and informs receptor occupancy modelling in laboratory research. The ~6-day half-life means that receptor engagement at all three target receptors (GIP, GLP-1, GcgR) is sustained over the week between doses, rather than delivering a brief peak of agonism followed by rapid clearance. For cell-based assays studying receptor internalisation, desensitisation, or downstream signalling dynamics over extended incubation periods, this pharmacokinetic characteristic is relevant to designing appropriate experimental time courses.
What is retatrutide’s CAS number and molecular weight?
Retatrutide has CAS number 2381627-57-0 and an approximate molecular weight of 4,869 Da. These identifiers are confirmed on the Pure Grade Labs product label and batch-specific COA. The molecular weight reflects retatrutide’s status as a larger, more complex peptide than semaglutide or native glucagon — a consequence of the multi-receptor binding pharmacophore incorporated into its structure.
Source Research-Grade Reta — Pure Grade Labs
Retatrutide (Reta) 10mg. HPLC ≥99% purity. Batch-specific COA. UK domestic stock. For laboratory research only — not for human consumption.
Investigational compound in Phase III trials. No approved indication. Prescription-only considerations apply in many jurisdictions.
Summary
Reta dosage — as a research question — refers to the dose levels studied in the Phase I and Phase II clinical trial programme for retatrutide, Eli Lilly’s triple GIP/GLP-1/glucagon receptor agonist. The Phase II NEJM 2023 data (Jastreboff et al.) studied four retatrutide dosage groups: 1mg, 4mg, 8mg, and 12mg weekly over 48 weeks. At 12mg, mean body weight reduction of 24.2% was observed — the highest published in any pharmacological obesity trial, exceeding tirzepatide’s 20.9% and semaglutide’s 14.9% from their respective pivotal trials. Weight loss trajectory at the 12mg dose had not plateaued at 48 weeks.
Retatrutide is not approved anywhere as of 2026 — it is an investigational compound in Phase III. The absence of approved prescribing information means Reta dosage data exists only in the research literature, and any use outside the trial context represents extrapolation beyond characterised parameters. The glucagon receptor agonism component distinguishes retatrutide from tirzepatide and is the subject of active mechanistic investigation into energy expenditure, hepatic fat mobilisation, and thermogenesis pathways.
Pure Grade Labs supplies Retatrutide 10mg at ≥99% HPLC-verified purity with batch-specific COA for laboratory research. Comparison research combinations with tirzepatide and semaglutide are available, as is the Metabolic Research Stack for broader incretin pharmacology research programmes.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038 [SURMOUNT-1]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 [STEP-1]
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503–515. doi:10.1056/NEJMoa2107519 [SURPASS-2]
- Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. The New Biology and Pharmacology of Glucagon. Physiol Rev. 2017;97(2):721–766. doi:10.1152/physrev.00025.2016
- Holst JJ, Gribble F, Horowitz M, Rayner CK. Roles of the Gut in Glucose Homeostasis. Diabetes Care. 2016;39(6):884–892. doi:10.2337/dc16-0351
Disclaimer: This article is for educational and informational purposes only and is directed at researchers and scientific professionals. Pure Grade Labs supplies retatrutide strictly as a research chemical for laboratory use only. Retatrutide is an investigational compound with no approved indication, no prescribing information, and no regulatory approval as of 2026. All products sold by Pure Grade Labs are not for human consumption, self-administration, or therapeutic use. Nothing in this article constitutes medical advice, prescribing guidance, dosing instructions, or a recommendation for use in humans. This article does not constitute clinical guidance of any kind. In jurisdictions where GLP-1 receptor agonists are regulated as prescription medicines, similar regulatory considerations may apply to retatrutide. Researchers should consult primary literature and apply appropriate scientific judgement. Pure Grade Labs is not responsible for outcomes arising from the use of research chemicals outside of approved laboratory research contexts.